Frank Pallone actually said...

I worry that this inappropriately treats biosimilars like generic drugs and will disincentivize manufacturers from entering the biosimilars ...

We have seen how our healthcare system has benefitted from the competition that comes with a robust market.

This is an important hearing, not only in terms of what is happening to biosimilars, but just the larger issue of drug pricing.

I supported the creation of the pathway for biosimilars and for empowering FDA with the authority and resources to ensure that biosimilars a...